About Nuclera Nucleics
Nuclera Nucleics is a company based in Cambridge (United Kingdom) founded in 2013 by Michael Chen and Gordon McInroy.. Nuclera Nucleics has raised $176.2 million across 14 funding rounds from investors including E Ink, M&G and G. K. Goh Holdings. The company has 134 employees as of December 31, 2023. Nuclera Nucleics has completed 1 acquisition, including E Ink. Nuclera Nucleics offers products and services including eProtein Discovery System, Instrument, Cartridge, Reagents, and Software. Nuclera Nucleics operates in a competitive market with competitors including Encodia, Tierra Biosciences, Amide Technologies, mk2 Biotechnologies and Kesmalea, among others.
- Headquarter Cambridge, United Kingdom
- Employees 134 as on 31 Dec, 2023
- Founders Michael Chen, Gordon McInroy
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nuclera Ltd
- Date of Incorporation 27 Aug, 2013
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuclera Nucleics
Nuclera Nucleics offers a comprehensive portfolio of products and services, including eProtein Discovery System, Instrument, Cartridge, Reagents, and Software. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
End-to-end system for rapid protein synthesis and screening in drug discovery
Device for cell-free protein expression and purification
Component for protein synthesis workflows
Materials for protein expression and optimization
Interface for managing protein prototyping processes
Unlock access to complete
Unlock access to complete
Funding Insights of Nuclera Nucleics
Nuclera Nucleics has successfully raised a total of $176.2M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $12 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Series C — $12.0M
-
First Round
First Round
(07 Jan 2014)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series C - Nuclera Nucleics | Valuation | Elevage Medical Technologies | |
| Oct, 2024 | Amount | Series C - Nuclera Nucleics | Valuation | Elevage Medical Technologies | |
| Jun, 2024 | Amount | Grant - Nuclera Nucleics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nuclera Nucleics
Nuclera Nucleics has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include E Ink, M&G and G. K. Goh Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Patient Square Capital is focused on health care investments.
|
Founded Year | Domain | Location | |
|
Venture capital co-investments are made in UK later-stage businesses.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in life sciences and deep tech.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nuclera Nucleics
Nuclera Nucleics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include E Ink. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Electronic paper displays for eBooks and devices are manufactured.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Nuclera Nucleics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nuclera Nucleics Comparisons
Competitors of Nuclera Nucleics
Nuclera Nucleics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Encodia, Tierra Biosciences, Amide Technologies, mk2 Biotechnologies and Kesmalea, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Technology platforms for integrative proteomic analysis are developed.
|
|
| domain | founded_year | HQ Location |
AI-based tools for protein development and custom synthesis are offered.
|
|
| domain | founded_year | HQ Location |
Automated peptide synthesis platform is developed with precision reagents.
|
|
| domain | founded_year | HQ Location |
Peptides and proteins are developed for life science applications.
|
|
| domain | founded_year | HQ Location |
Protein homeostasis modulators are developed for therapeutic applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nuclera Nucleics
Frequently Asked Questions about Nuclera Nucleics
When was Nuclera Nucleics founded?
Nuclera Nucleics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Nuclera Nucleics located?
Nuclera Nucleics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Nuclera Nucleics?
Michael Chen is the current CEO of Nuclera Nucleics. They have also founded this company.
Is Nuclera Nucleics a funded company?
Nuclera Nucleics is a funded company, having raised a total of $176.2M across 14 funding rounds to date. The company's 1st funding round was a Grant of $1.46M, raised on Jan 07, 2014.
How many employees does Nuclera Nucleics have?
As of Dec 31, 2023, the latest employee count at Nuclera Nucleics is 134.
What does Nuclera Nucleics do?
Founded in 2013 in Cambridge, United Kingdom, the company operates in the biotechnology sector. A desktop bioprinter known as eProtein is developed by combining eProtein synthesis with eDrop digital microfluidics technology. High-value proteins are produced through this system, enabling on-demand gene and protein synthesis. Operations focus on advancing accessible tools for biological research and applications.
Who are the top competitors of Nuclera Nucleics?
Nuclera Nucleics's top competitors include Encodia, Tierra Biosciences and Amide Technologies.
What products or services does Nuclera Nucleics offer?
Nuclera Nucleics offers eProtein Discovery System, Instrument, Cartridge, Reagents, and Software.
How many acquisitions has Nuclera Nucleics made?
Nuclera Nucleics has made 1 acquisition, including E Ink.
Who are Nuclera Nucleics's investors?
Nuclera Nucleics has 17 investors. Key investors include E Ink, M&G, G. K. Goh Holdings, Elevage Medical Technologies, and Patient Square Capital.
What is Nuclera Nucleics's valuation?
The valuation of Nuclera Nucleics is $161.23M as of Dec 2021.